Sanofi’s Dengue Vaccine To Market in 2015

Sanofi Pasteur announces a successfull phase III trial in Latin America and plans to enter the market in 2015 The vaccines division of Sanofi  has published the results of their second phase III trial of their dengue vaccine candidate. The study, published in The New England Journal of Medicine, looked at the efficacy of the vaccine in Latin America, and …

Takeda acquires Inviragen and their DENVax vaccine

Japanese firm Takeda has announced that it will acquire Inviragen for an upfront payment of US$35 million, and future payments of up to $215 million. With the acquisition also comes Inviragen's advanced vaccine candidate against dengue, DENVax, which recently moved into the second stage of Phase II trials. "The acquisition of Inviragen supports Takeda's overall research and development programs, long-term …

#Takeda’s new #vaccine development unit headed by Dr Rajeev Venkayya

It was announced shortly before the holidays that Dr. Rajeev Venkayya, the director of vaccine delivery in the Global Health Program at the Bill & Melinda Gates Foundation, will be heading up the new vaccine development unit at Takeda as of January this year.   Takeda will aim to focus their efforts towards expanding into pediatric vaccines on top of …